AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
BioStem Technologies, Inc.
Video analysis: BSEM
All videosNo video analysis for this stock yet. Request one from our team.
News: BSEM
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Additions extend BioStem's hospital channel to its BioRetain® wound care line PR Audio: POMPANO BEACH, Fla., September 4, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc.
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nation's largest Group Purchasing Organizations (GPOs).
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
POMPANO BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the H.C.
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility.
Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation. Insider and Institutional Ownership 1.0% of Enlivex
BioStem Technologies to Present at the Sidoti MicroCap Conference
POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Sidoti MicroCap Virtual Conference.
BioStem Technologies Q2 Earnings Call Highlights
BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage and a full quarter of contribution from its acquired business.
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
